The Medtronic share has been stable in recent weeks, despite slight fluctuations in the market. The medical technology group is benefiting from its leading position in innovative therapies and devices. The MiniMed 780G insulin pump with meal detection technology, recently approved by the FDA, is particularly promising. This enables even more precise blood sugar control for diabetes patients and underlines Medtronic’s innovative strength.
Solid finances and attractive dividend
With a dividend yield of 3.32%, Medtronic shares remain interesting for investors. Analysts see further potential as the company is well positioned in high-growth areas such as robot-assisted surgery and cardiac therapies. The quarterly figures expected in November will provide information on short-term developments.
Advertisement
Medtronic shares: Buy or sell?! New Medtronic analysis from September 22 provides the answer:
The latest Medtronic figures speak for themselves: Medtronic shareholders urgently need to take action. Is it worth buying or should you sell? Find out what to do now in the current free analysis from September 22nd.
Medtronic: Buy or sell? Read more here…
